Has John Hanson received payments from drug or device companies?

Yes. Drug and device makers reported $28,318 in general payments to John Hanson across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Hanson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Hanson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Hanson

Gastroenterology · Charlotte, NCNPI 1164470175

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $24,800 of the $28,318 with a category attached, or 87.6%. Pfizer accounts for 79.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $20,105 and has fallen 99.5% since, to $110 in 2025. Among gastroenterology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,318in general payments, 2019–2025

Across 29 payments — averaging $976.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$22K
AbbVie$4K
E.r. Squibb & Sons, L.L.C.$1K
Takeda Pharmaceuticals U.S.A., Inc.$156
Boehringer Ingelheim$110
Bristol Myers Squibb$97
plus $152 from 2 others

$856,575in research payments, 2019–2025

Across 192 payments — averaging $4461.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$549K
Bristol Myers Squibb$153K
Takeda Pharmaceuticals U.S.A., Inc.$124K
E.r. Squibb & Sons, L.L.C.$23K
Janssen Research & Development, LLC$4K
Eli Lilly$2K

What the payments were for

Consulting fees$1,0504%
Speaking & faculty fees$24,80088%
Travel & lodging$8393%
Food & beverage$1,5586%
Education$710%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	13	$22,435
AbbVie	7	$4,207
E.r. Squibb & Sons, L.L.C.	2	$1,162
Takeda Pharmaceuticals U.S.A., Inc.	3	$156
Boehringer Ingelheim	1	$110
Bristol Myers Squibb	1	$97
Gilead	1	$85
Johnson & Johnson	1	$67

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XELJANZ$22,341
Rinvoq$119
Entyvio$103

How this compares

$28,318 in reported general payments places this provider in the 90th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina →

Other gastroenterology in Charlotte

Stephen DealCharlotte$945K
Fred FowlerCharlotte$932K
Nilesh LodhiaCharlotte$735K
Oscar BrannCharlotte$136K
Philippe ZamorCharlotte$132K
Kent HoltzmullerCharlotte$131K
Baharak MoshireeCharlotte$105K
Sagar PatelCharlotte$85K
Olanrewaju JimohCharlotte$67K
Sean RudnickCharlotte$60K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →